


ACT-Accelerator Update

Upcoming products

MSCOVID-19 BRIEFING

5 AUGUST 2021

ACT now. ACT together to accelerate the end of the COVID-19 crisis



4 key ACT-Accelerator activities thru Sept:

ACT-A Q2 Impact Update




- details recent achievements, needs
- 12-page overview, with 2-pagers per Pillar



ACT-A Delta Appeal




- urgent ACT-A needs driven by Delta crisis
- 4-month budget (Aug – Nov 2021)



ACT-A Strategic Review



- analyze results, best practice & gaps
- recommendations to enhance ACT-A



Strategy & Budget refresh



- update ACT-A priorities & timeline
- generate new budget (Oct 21-Sept 22)



ACT-A Quarter 2 Update

ACT-A Quarter 2 Update (Apr-Jun 2021)

published online 5 August

12-page update

Achievements

Urgent Needs

Country Profile

ACTaccelerator ACCESS TO COVID-19 TOOLS

Quarterly Update Q2: 1 April - 30 June 2021

ACT-A overall financing situation
In just over 15 months **36.1B** USD Billion
US\$1.77 billion to the ACT-Accelerator

ACT-A 2020-21 budget as of Sept 2020: **36.1B**

Cost adjustments: **-4.9B**

Contributions: **17.7B**

2021 funding gap: **16.8B**

Confirmed cases & deaths
From March 2020 to 1 July 2021: **182 million cases**, **4 million deaths**
Q2 from April 2021 to 1 July 2021: **63 million cases**, **3 million deaths**

State of the global pandemic
The COVID-19 pandemic, despite global efforts, is nowhere near over. Four variants of concern dominate the epidemiology and there are fears that new, and possibly more dangerous, variants may emerge, and be even more challenging to control.

Q2: ACT-Accelerator pillar achievements

- R&D and Product Assessment:** Obtained WHO Emergency Use Listing for 2 treatments and 3 vaccines; Support for development of 2 novel antiviral programs, 9 outpatient treatments and 8 vaccine candidates; Currently under study 5 clinical trials for new vaccines and 10 affordable self-tests.
- Market Shaping & Manufacturing:** Invested in expanding manufacturing capacity of 2 diagnostics tests to enable regional diversification; Signed MoUs with 2 multinational oxygen suppliers to set up long-term agreements; Groundwork to establish regional Hubs to expand the footprint of vaccine production.
- Procurement:** Procured 29+ million vaccine doses; 22+ million tests; US\$223m worth of oxygen supplies; US\$35m worth of treatments inc. dexamethasone; US\$23m worth of personal protective equipment; Deployed assistance during oxygen crises in India, Bangladesh & Zambia; Signed Advance Purchase Agreements with manufacturers for over 2 billion vaccine doses through COVAX.
- Demand Generation & In-country Delivery:** Established a system to model country-level vaccine utilization and absorption; Made first disbursements from US\$75m of COVID-19 Delivery Support to countries; Knowledge sharing on sequencing through new ACT-A sequencing WG; Advocacy for oxygen supply through Every Breath Counts; Established Implementation Monitoring Review mechanism to coordinate timely identification of country-level bottlenecks; Technical assistance to countries and capacity building of health workers.

Mobilizing for equity
Increased global discourse and new initiatives reinforced the imperative to achieve equity in the fight against the pandemic. Leaders at G20 committed to sharing 870 million vaccine doses over the next year; the **LMC** positioned its US\$50 bn plan to end the pandemic as the best investment ever, with a US\$9 billion payoff up to 2035; the **Independent Panel for Pandemic Preparedness** and **G20 Finance Ministers and Central Bank Governors** called for the ACT-A to be fully funded, and the **G20 Global Health Summit** resulted in multiple commitments to the ACT-Accelerator.

Advocacy support for the Act-Accelerator

- May 8th: Global citizen 'Concert to Reshape the World'
- May 21st: Global Health Summit
- May 24th - June 1st: WHO/World Health Assembly
- June 2nd: COVAX AMC meeting
- June 3rd - 4th: G7 Health Ministers Meeting
- June 11-13th: G7 Summit
- June 30th: WB, IMF, WHO, WTO Call

Urgent Needs
The Covid-19 delta variant is surging and is expected to become the dominant strain circulating worldwide. The delta variant is now present in 124 countries!

- Accelerated transmission** is resulting in increased deaths globally. The international community is bracing for multiple imminent surges. Inequality in access to life-saving COVID-19 tools has never been more apparent.
- Hard-won progress** in populations with high COVID-19 immunization coverage is in jeopardy. Whilst low-income countries with much lower coverage rates are at higher risk of severe disease and hospitalization, with healthcare systems being overwhelmed.
- People in low-income and most lower-middle-income countries do not have **adequate access to testing** - this leaves the world blind to understanding where the disease is, and how it is changing.
- Avoidable death and unsustainable pressure on health systems is mounting in many countries due to **insufficient access to oxygen and PPE**.

This requires a Rapid ACT-A Delta Response (RADAR)
US\$7.7billion is urgently needed to combat the delta variant surge and US\$3.8 billion to ensure the vaccine supply

- Scale-up Testing** (US\$4.4 billion): Procure US\$2.4 billion worth of Covid-19 tests to put all low-income countries and lower-middle-income countries on the path towards a ten-fold increase in COVID-19 testing and get all countries up to adequate testing levels to help locate variants of concern and identify where public health interventions are most needed.
- Deliver Oxygen** (US\$1.2 billion): Invest US\$1.2 billion to rapidly address acute oxygen needs to treat the seriously ill, and control the exponential death surges caused by the delta variant.
- Protect health workers** (US\$1.7 billion): Procure US\$1.7 billion worth of personal protective equipment to keep 2 million essential health workers safe while they vaccinate, test and care for the sick, and to help prevent the collapse of health systems where the healthcare workforce is already understaffed.

Q2 ACT-A Country profile: Kenya

COVID-19 response
Daily tests/100k inhab: **10.5**
Vaccine administered: **1.4m**
Fully vaccinated people: **460k**
Population: **52 million**
GDP percapita (2019): **1,816 US\$**

ACT-Accelerator impact

- Diagnostics** (US\$ 1.6m+): Delivered to Kenya through the diagnostics consortium since the start of the pandemic, of which 11m during Q2 2021. Kenya has relied on a limited number of PCR testing facilities and reagents. The availability of Ag-ROTs has significantly increased the number of people tested, and will enable the country to respond better to surges.
- Therapeutics** (US\$ 0.5m+): Including oxygen accessories (US\$0.4m) such as 1300+ pulse oximeters, 70 voltage stabilizers, 30 oxygen analyzers and 80 oxygen concentrators. Kenya is one of 13 countries in Africa taking part in ANTICOV trials of new treatments for mild-to-moderate infection.
- Vaccines** (US\$ 1.02m+): Delivered to Kenya, plus expected 180k dose donations from France and additional donations from Greece in Q2. Supplied in March 2021, vaccination programmes started almost immediately - prioritizing frontline health workers and those at most risk of severe disease. UNICEF delivered an additional 72,000 doses in May, redeployed from South Sudan.
- Health Systems Connector** (US\$ 0.5m+): UNICEF, the World Bank and WHO are supporting the Ministry of Health in planning, technical assistance, training, capacity building, risk communications and community engagement. UNICEF supplied Kenya US\$897,398 worth of essential supplies including molecular diagnostics US\$434,337, syringes US\$182,504, face masks and Ngisa US\$77,899, diagnostic consumables US\$69,953, coveralls US\$43,816, safety boxes US\$18,243, isolation gowns US\$4,251, goggles US\$5,080, medical devices US\$3,921, disposable face shields US\$3,361, heavy-duty gloves US\$1,902 and boots covers US\$1,251.

Emergency response and delivery (US\$4.4 billion): Rollout emergency response and delivery support to help countries identify and address key bottlenecks for the effective deployment and use of COVID-19 tools. This is essential as coverage of COVID-19 vaccines is ramped up in the coming months.

The ACT-Accelerator Partners: **Gavi**, **CEPI**, **COVAX**

Source: WHO COVID-19 dashboard data; FMO test tracker; ACT-A Partners

ACT-A Q2 Update

Pillar-specific '2 pagers'

ACT-A Diagnostics Pillar

Q2 Update: 1 April - 30 June 2021

US\$ Bn

ACT-A 2020-21 budget as of Sept 2020: 6.0
Cost adjustments: 3.7
Commitments: 1.0
2021 funding gap: 0.7
2021 funding gap: 8.6

Legend: Gap (Red), Adjustments (Light Blue), Pending (Dark Blue), Received (Light Blue)

Urgent actions needed

- Procure US\$2.4 bn worth of Covid-19 tests to put all low-income countries and lower-middle-income countries on the path towards a ten-fold increase in COVID-19 testing and get all countries up to satisfactory testing levels
- Invest US\$0.1 bn in R&D, market shaping and manufacturing, technical assistance and demand-generation activities to ensure equitable access to diagnostics tools

Resources needed US\$ 2.5 billion

Since the beginning of the pandemic:

- more than 84 million molecular and antigen rapid diagnostic tests (RDTs) have been procured
- regionalized manufacturing has been given a boost through technology transfers
- the average price of antigen RDTs decreased from US\$5 to US\$2.5 (since September 2020)
- over 70 countries have been supported to expand laboratory infrastructure and ramp-up testing

Widespread and effective testing is critical for disease surveillance, outbreak detection, identification of new variants, patient diagnosis and contact tracing, and to measure the efficacy of COVID-19 vaccines particularly in light of emerging new variants. It also provides data to target public health measures such as lockdowns, distancing and mask policies, tailor advocacy and

risk communication and community engagement strategies to increase access to and uptake of diagnostics. Yet test-and-trace programmes globally have been chronically underfunded and now the reliance on vaccines is overshadowing the urgent need for heightened testing.

Variants can arise anywhere in the world and have the potential to decrease the effectiveness of existing tests, treatments, and vaccines. Ensuring rapid identification and robust surveillance of variant strains is therefore critical to ensure the progress made to date is not erased.

© The Global Fund / Photo: C&P

Diagnostics Achievements for Equity

R&D and Product Assessment

- Continued to assess diagnostic tests to inform government procurement of quality COVID-19 tests (90 to date since April 2020)
- Received and reviewed nearly 90 applications to bring affordable, accurate self-testing products to countries, with 10 now shortlisted for pilot programmes

90+

Market shaping and manufacturing

- Invested in the manufacturing of two quality and affordable rapid diagnostic tests (RDTs) to increase global manufacturing capacity
- Published new WHO Recommendations for national SARS-CoV-2 testing strategies

Procurement

- Procured 22+ m COVID-19 diagnostics supplies for LMICs through the Diagnostics consortium
- Countries awarded US\$477 m for diagnostics
- Partner negotiations with suppliers resulted in 40-80% price reductions; the most affordable antigen RDT for COVID-19 was introduced at US\$2.55 and a record low price of US\$2.80 was reached for an RT-PCR test for manual use

22+ million
US\$ 177 million

Demand generation & in-country delivery

- Continued testing pilot programmes in countries (60 to date since April 2020) and planned operational research studies (15 to date since April 2020)
- Launched Antigen Rapid Diagnostic Test (Ag RDT) modelling consortium to explore the public health impact of Ag RDTs in different settings
- Launched Genomic Surveillance Working Group; conducted baseline mapping of global sequencing capacity
- Held first Country Roundtable, to enable bi-directional communication and information sharing with in-country implementers
- Supported 73 countries with risk communication and community engagement activities to build trust and increase testing and tackle misinformation around COVID-19
- Updated web-based SARS-CoV-2 Ag RDT training package co-led by WHO and FMO - training accessed 1275 times in Q2 (from 95 countries or territories)

1275 times

ACT-A Therapeutics Pillar

Q2 Update: 1 April - 30 June 2021

US\$ Bn

ACT-A 2020-21 budget as of Sept 2020: 6.6
Cost adjustments: -2.7
Commitments: 0.8
2021 funding gap: 0.1
2021 funding gap: 3.2

Legend: Gap (Red), Adjustments (Light Blue), Pending (Dark Blue), Received (Light Blue)

© UNICEF / GPH

Urgent actions needed

- Invest US\$1.2 bn to rapidly address acute oxygen needs to treat the seriously ill, and control the exponential death surges caused by the delta variant
- Invest US\$0.3 bn in R&D, market shaping, manufacturing, strengthening of supply chains and capacity of health workers to deliver quality therapeutics

Resources needed US\$ 1.5 billion

The Therapeutics Pillar, co-led by Wellcome, Unilever and WHO, supported the identification of the first life-saving therapy for COVID-19 - dexamethasone - and provided global guidance on its use. The Global Fund and UNICEF have led the work on procurement and deployment of COVID-19 therapeutics including oxygen and related products.

The COVID-19 Oxygen Emergency Taskforce was launched by Unilever, Wellcome and WHO to assess and address COVID-19 surges in demand to cut preventable deaths. Global demand for medical oxygen is currently more than a dozen times greater than before the pandemic. Pre-publication estimates suggest that around 1 million critically-ill COVID-19 patients in low- and middle-income countries need 2.2 million oxygen cylinders (15.1 million cubic metres) per day.

From the start of the pandemic over US\$97 million of oxygen provisions (2.7 million litres) have been shipped to countries. In the last quarter, US\$219 million in grants has been awarded to countries for the procurement of oxygen provisions, including oxygen concentrators and new public oxygen plants.

ACT-A Vaccines Pillar

Q2 Update: 1 April - 30 June 2021

US\$ Bn

ACT-A 2020-21 budget as of Sept 2020: 16.0
Cost adjustments: -4.3
Commitments: 10.8
Contribution to AMC beyond start need: 6.2
2021 funding gap: 1.4
2021 funding gap: 0.9

Legend: Gap (Red), Adjustments (Light Blue), Pending (Dark Blue), Received (Light Blue)

Urgent actions needed

- Close the funding gap for in-country delivery, including to humanitarian and fragile settings, with further investment to increase coverage in the coming months
- Invest to continue critical R&D to meet the challenges of a rapidly evolving pandemic
- Invest US\$3.8 bn beyond the 2021 ask, to guarantee supply of 750m doses of vaccines for 2022, by exercising options to buy new rather than lose the doses due to lack of funds

Resources needed US\$ 4.7 billion

COVAX doses delivered
From April 1st to July 1st 2021

Legend: 0, 100k - 500k, 1M - 2M, 1 - 100k, 500k - 1M, >2M

COVAX, the ACT-Accelerator's Vaccines Pillar is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the World Health Organization (WHO) - working in partnership with UNICEF, as key implementing partner, and with vaccine manufacturers, civil society organizations and the World Bank.

COVAX investments have accelerated the research and development of a portfolio of 30 candidates across four technology platforms. COVAX has shipped a total of 92.9 million vaccines to 134 countries and economies (as of 1 July 2021). Of these 60.1 million doses were shipped to 81 advance market commitment (AMC) countries and economies. It is expected that a further 1.8 billion doses will be available for shipment by the end of 2021; of these, AMC participants are expected to receive about 1.5 billion doses in total, including donated doses, equivalent to approximately 2% population coverage (excluding India). For latest COVAX vaccine roll-out data visit [GAVI, the Vaccine Alliance](#).

COVAX has laid the groundwork to secure further doses through contributions from donors and negotiations with manufacturers.


In the meantime, only 14% of doses have been administered in LICs / LMICs while they represent 48.7% of the world's population. WHO has called for 50% vaccine coverage in all countries by end of September 2021.

A Manufacturing Task Force has been established to identify and resolve manufacturing issues impeding equitable access to vaccines through COVAX. The Taskforce is urgently addressing short-term challenges and bottlenecks and working with a consortium in South Africa to transfer technology and establish a vaccine manufacturing hub in the region, ensuring long-term regional health security.

ACT-A Delta Appeal (release target 6 August 2021)

Rapid ACT-A Delta Response – context (3 August 2021)

New confirmed cases, by date of report (n = 198,778,175)



Rapid ACT-A Delta Response: US\$ 7.7 B appeal and US\$ 3.8bn to ensure continued vaccine supply



10-fold increase in testing esp. to boost in LICs/LMICs



\$2.4bn



Rapidly address acute oxygen needs to treat seriously ill



\$1.2bn



Provide 2 million healthcare workers basic PPE



\$1.7bn



Ensure essential R&D to improve tools for evolving virus



\$1.0bn



Support countries with flexible operational funds and Technical Assistance to roll out Vx, Dx, Ox & PPE



\$1.4bn



Exercise options to secure additional 760 m vaccine doses for AMC countries in 2022



\$3.8bn

**Delta Appeal
\$7.7b**

**Continued
vaccine supply
\$3.8b**

ACT-A Strategy & Budget Refresh

ACT-A Strategy & Budget Refresh | evolving context & shifts

Context

- **Diverging epidemiology:** 1 pandemic with 2 different impacts
- **Increasing inequity:** escalating HIC/LIC gap in coverage with Dx, Vx, Ox
- **More complex ecosystem:** many players/mechanisms delivering COVID-19 tools

...From




...To

Shifts


- | | |
|---|--|
| 1. being <i>the</i> global solution | being 'a key solution' in the global context |
| 2. delivery focus encompasses all countries | target-driven delivery to LICs, LMICs & key UMICs |
| 3. 'one-off' products | evolving portfolio adapted to evolving pandemic |
| 4. supply solutions for an acute crisis | sustainable solutions (for 'endemic'/evolving virus) |
| 5. grant-based financing | mix of grants, concessional and domestic financing |

ACT-A Strategy & Budget Refresh | time-horizon & development process

Time-horizon
(12 months)



Timeline to develop



ACT-A Strategic Review

ACT-A Strategic Review | status at 5 August 2021

1. External firm - competitive selection
 - 4 intentions to bid, 3 bids received



**Dalberg Global
Development Advisors**

2. **Kick-off with Sponsors** - 3 DG Special Envoys for ACT-A (2 August)

3. Key Next Steps


Confirm Reference Group (*by 6 August*) :

- **Comment & advise** on Inception Report & prelim findings
- **Entry point for** their constituencies
- co-Hosts (WHO/EC), Council MSs, ACT-A co-convening agencies, Industry, CSOs

Inception Report

ACT-A Product Timeline

ACT-A Timeline for key products





ACTaccelerator

ACCESS TO COVID-19 TOOLS